These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19917874)

  • 1. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
    Cooper-DeHoff RM; Wen S; Beitelshees AL; Zineh I; Gums JG; Turner ST; Gong Y; Hall K; Parekh V; Chapman AB; Boerwinkle E; Johnson JA
    Hypertension; 2010 Jan; 55(1):61-8. PubMed ID: 19917874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
    Manrique C; Johnson M; Sowers JR
    Hypertension; 2010 Jan; 55(1):15-7. PubMed ID: 19917873
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
    Moore MJ; Gong Y; Hou W; Hall K; Schmidt SO; Curry RW; Beitelshees AL; Chapman A; Turner ST; Schwartz GL; Bailey K; Boerwinkle E; Gums JG; Cooper-DeHoff RM; Johnson JA
    Pharmacotherapy; 2014 Nov; 34(11):1132-40. PubMed ID: 25202885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
    Smith SM; Gong Y; Turner ST; Cooper-DeHoff RM; Beitelshees AL; Chapman AB; Boerwinkle E; Bailey K; Johnson JA; Gums JG
    Am J Hypertens; 2012 Mar; 25(3):359-65. PubMed ID: 22089105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
    Gong Y; McDonough CW; Beitelshees AL; Karnes JH; O'Connell JR; Turner ST; Chapman AB; Gums JG; Bailey KR; Boerwinkle E; Johnson JA; Cooper-DeHoff RM
    Pharmacotherapy; 2014 Feb; 34(2):123-30. PubMed ID: 24122840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.
    Damian DJ; McNamee R; Carr M
    BMC Cardiovasc Disord; 2016 Oct; 16(1):188. PubMed ID: 27716064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.
    Lacourcière Y; Lefebvre J; Provencher P; Poirier L
    Br J Clin Pharmacol; 1993 Feb; 35(2):121-7. PubMed ID: 8443029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
    Smith SM; Anderson SD; Wen S; Gong Y; Turner ST; Cooper-Dehoff RM; Schwartz GL; Bailey K; Chapman A; Hall KL; Feng H; Boerwinkle E; Johnson JA; Gums JG
    Pharmacotherapy; 2009 Oct; 29(10):1157-65. PubMed ID: 19792989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Lakshman MR; Reda DJ; Materson BJ; Cushman WC; Freis ED
    Arch Intern Med; 1999 Mar; 159(6):551-8. PubMed ID: 10090111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
    Okin PM; Hille DA; Wiik BP; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
    Diabet Med; 2013 Oct; 30(10):1189-97. PubMed ID: 23587029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination antihypertensive therapy in patients with an increased risk profile].
    Bartens W; Nauck M; Wanner C
    Med Klin (Munich); 1996 Oct; 91(10):626-31. PubMed ID: 9019639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
    Fogari R; Zoppi A; Malamani GD; Marasi G; Vanasia A; Villa G
    Br J Clin Pharmacol; 1995 May; 39(5):471-6. PubMed ID: 7669481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.
    Widmann L; van der Does R; Hörrmann M; Machwirth M
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S143-6. PubMed ID: 1974505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
    Ofili EO; Zappe DH; Purkayastha D; Samuel R; Sowers JR
    Am J Ther; 2013 Jan; 20(1):2-12. PubMed ID: 22248871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.